Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Surg Oncol. 2014 May;109(6):556-60. doi: 10.1002/jso.23529. Epub 2013 Dec 11.

Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma.

Author information

  • 1Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Abstract

BACKGROUND:

Ampullary (AMP-A) and duodenal adenocarcinomas (DA) are rare tumors. The literature regarding treatment and outcome is very limited. The objective of this project is to compare the outcomes of AMP-A and DA.

METHODS:

The records for AMP-A and DA patients between July 1995 and July 2012 at Emory University were reviewed for demographics, pathology, treatment, and survival. Survival rates were estimated by Kaplan-Meier method and compared with log-rank test. A Cox proportional hazard model was fitted to estimate the adjusted effect of AMP-A versus DA on overall survival (OS).

RESULTS:

Ninety-five AMP-A and 66 DA patients were identified. No significant difference between patients with DA and AMP-A was observed for age, gender, or grade. DA presented with larger tumors and higher stages. Treatment included surgery, surgery followed by adjuvant therapy or chemotherapy alone. No OS difference was observed when controlled for stage. AMP-A was sub-classified into intestinal (IAMP), pancreaticobiliary (PBAMP), and unspecified types. IAMP tended to present at a higher grade (P = 0.045) than PBAMP. No OS difference between the IAMP and PBAMP was observed.

CONCLUSIONS:

After accounting for stage, OS was not significantly different for AMP-A and DA patients. There was no OS difference comparing PBAMP with IAMP.

© 2013 Wiley Periodicals, Inc.

KEYWORDS:

adenocarcinoma; ampullary; ampullary subtypes; duodenal; survival

PMID:
24338561
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk